Altimmune, Inc. (NASDAQ:ALT) Shares Sold by Beirne Wealth Consulting Services LLC

Beirne Wealth Consulting Services LLC reduced its stake in Altimmune, Inc. (NASDAQ:ALT) by 2.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 294,458 shares of the company’s stock after selling 8,342 shares during the period. Altimmune accounts for approximately 0.8% of Beirne Wealth Consulting Services LLC’s holdings, making the stock its 29th biggest position. Beirne Wealth Consulting Services LLC’s holdings in Altimmune were worth $2,123,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. acquired a new stake in Altimmune in the fourth quarter worth approximately $109,000. PFG Investments LLC acquired a new stake in shares of Altimmune in the fourth quarter valued at $96,000. SG Americas Securities LLC boosted its stake in Altimmune by 36.7% during the fourth quarter. SG Americas Securities LLC now owns 47,060 shares of the company’s stock valued at $339,000 after buying an additional 12,624 shares in the last quarter. Kraematon Investment Advisors Inc. bought a new position in Altimmune during the fourth quarter valued at about $222,000. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in Altimmune by 18.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 205,590 shares of the company’s stock worth $1,482,000 after acquiring an additional 31,482 shares during the period. 78.05% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 target price for the company. UBS Group assumed coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research report on Wednesday, February 5th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $20.83.

Altimmune Trading Up 1.8 %

Shares of ALT stock opened at $6.49 on Wednesday. Altimmune, Inc. has a 12 month low of $5.28 and a 12 month high of $14.84. The stock has a 50 day moving average of $7.19 and a two-hundred day moving average of $7.18.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.